SEARCH?

Search anything and hit enter

The Answer to America’s Opioid Epidemic? CBD, This Study Suggests

Findings in a new research review indicate that cannabidiol (CBD) can help those addicted to opioids by reducing cravings and withdrawal symptoms.

Studies indicate that cannabidiol (CBD), a natural cannabinoid found in cannabis, effectively reduces the cravings and withdrawal symptoms in those addicted to opioids, a new research review concludes. Yasmin L. Hurd, PhD, the Director of the Center for Addictive Disorders for the Mount Sinai Behavioral Health System, examined the findings of animal studies and a small human pilot and published her findings in the journal Trends in Neuroscience.

Doctors commonly prescribe opioids for the management of severe or chronic pain. The powerful medications bind to opioid receptors throughout the brain, spinal cord, and other areas of the body, which in turn reduce the perception of pain and produce a sense of well being. Opioids, while effective, carry a high risk of abuse and addiction, and every day in the U.S. 78 people die from an opioid-related overdose.

Hurt found that findings in animal model studies indicate that cannabis can help in the treatment efforts of those addicted to opioids. In particular, there’s accumulating evidence suggesting that CBD reduces both withdrawal symptoms and the rewarding properties of opioids to decrease cravings.

“If you look at both drugs and where their receptors are, opioids are much more dangerous in part because of the potential for overdose. The opioid receptors are very abundant in the brainstem area that regulates our respiration so they shut down the breathing center if opioid doses are high,” said Dr. Hurd. “Cannabinoids do not do that. They have a much wider window of therapeutic benefit without causing an overdose in adults.”

“Surprisingly, the scientific community has been largely missing from most conversations and policymaking decisions regarding the legalization of marijuana for medical purposes. Normally, preclinical models provide the foundation for clinical trials and then, after years of rigorous, structured scientific investigations, accrued evidence is evaluated by federal agencies to determine whether a particular compound should be approved for the treatment of specific symptoms/disease,” said Dr. Hurd. “For marijuana, such a bar has not been met. Decisions across the country have been driven, in large part, by anecdotal reports and lobbying efforts by a growing marijuana industry. Despite the challenges of prescribing the medical use of a plant without the normal, rigorous clinical study process and within our existing clinical structure, specific constituents of the plant could be more easily developed for medical indications.”

Hurd is now running a larger trial to further investigate whether cannabis could help people that are addicted to opioid substances.

“We have to be open to marijuana because there are components of the plant that seem to have therapeutic properties, but without empirical-based research or clinical trials, we’re letting anecdotes guide how people vote and how the policies are going to be made,” said Dr. Hurd. “For one of the first times in U.S. history, it is the general public and politicians, not scientists and physicians, who are determining the medical value of this drug in states where marijuana use has been legalized for medical purposes. Clearly, the legalization of marijuana has outpaced the science. But if we want to be able to accurately say something is medical marijuana, we have to prove that it is, indeed, medicinal.”

You can read the entire study, “Cannabidiol: Swinging the Marijuana Pendulum From ‘Weed’ to Medication to Treat the Opioid Epidemic” via Cell Press.

Enter your email below

Follow us on social networks

DIGITAL CONTENT WRITER

DIGITAL CONTENT WRITER

This article may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.

Food and Drug Admistration (FDA) Disclosure

These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease. Always check with your physician before starting a new dietary supplement program.

Leaving Our Website Disclaimer: If we have a research link to a website where we sell products or have product information you are now leaving the medicalmarijuanainc.com website. Links to any informational websites are provided solely as a service to our users.

The link provides additional information that may be useful or interesting and has no aliation to the promotion, sale and distribution of Medical Marijuana Inc. products. The link does not constitute an endorsement of these organizations by Medical Marijuana Inc. and none should be inferred. Please view our full Terms Of Use Agreement for more information and the terms and conditions governing your use of this site.

* Cannabidiol (CBD) is a naturally-occurring constituent of the industrial hemp plant.

Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). The company does grow, sell and distribute hemp based products.